急性髓系白血病的新药
New drugs in acute myeloid leukemia.
作者信息
Kadia T M, Ravandi F, Cortes J, Kantarjian H
机构信息
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA.
出版信息
Ann Oncol. 2016 May;27(5):770-8. doi: 10.1093/annonc/mdw015. Epub 2016 Jan 22.
Abstract
The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for the past four decades. Improvements in supportive care and modifications to the dose and schedule of existing agents have led to steady improvements in outcomes. However, developing new therapies for AML has been challenging. Although there have been advances in understanding the biology of AML, translating this knowledge to viable treatments has been slow. Active research is currently ongoing to address this important need and several promising drug candidates are currently in the pipeline. Here, we review some of the most advanced and promising compounds that are currently in clinical trials and may have the potential to be part of our future armamentarium. These drug candidates range from cytotoxic chemotherapies, targeted small-molecule inhibitors, and monoclonal antibodies.
摘要
在过去的四十年里，急性髓系白血病（AML）的标准治疗方法没有显著变化。支持性护理的改善以及对现有药物剂量和给药方案的调整使得治疗效果稳步提高。然而，开发AML的新疗法一直具有挑战性。尽管在了解AML生物学方面取得了进展，但将这些知识转化为可行的治疗方法进展缓慢。目前正在进行积极的研究以满足这一重要需求，并且有几种有前景的候选药物正在研发中。在此，我们回顾一些目前正在进行临床试验且可能有潜力成为我们未来治疗手段一部分的最先进、最有前景的化合物。这些候选药物包括细胞毒性化疗药物、靶向小分子抑制剂和单克隆抗体。
相似文献
1
New drugs in acute myeloid leukemia.急性髓系白血病的新药
Ann Oncol. 2016 May;27(5):770-8. doi: 10.1093/annonc/mdw015. Epub 2016 Jan 22.
2
Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).急性髓系白血病（急性早幼粒细胞白血病除外）药物治疗的进展
Drug Des Devel Ther. 2018 Apr 30;12:1009-1017. doi: 10.2147/DDDT.S161199. eCollection 2018.
3
Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.急性髓系白血病的靶向治疗：聚焦于FLT-3抑制剂和ABT199。
Expert Rev Hematol. 2017 Oct;10(10):863-874. doi: 10.1080/17474086.2017.1366852. Epub 2017 Aug 21.
4
New Treatment Options for Acute Myeloid Leukemia in 2019.2019年急性髓系白血病的新治疗选择
Curr Oncol Rep. 2019 Feb 4;21(2):16. doi: 10.1007/s11912-019-0764-8.
5
New drugs in acute myeloid leukemia.急性髓系白血病的新药
Semin Oncol. 2008 Aug;35(4):439-48. doi: 10.1053/j.seminoncol.2008.04.014.
6
Current and emerging therapies for acute myeloid leukemia.急性髓系白血病的现有和新兴疗法。
Clin Ther. 2009;31 Pt 2:2349-70. doi: 10.1016/j.clinthera.2009.11.017.
7
New treatment for acute myelogenous leukemia.急性髓系白血病的新疗法。
Expert Opin Pharmacother. 2015 Jan;16(1):95-106. doi: 10.1517/14656566.2015.981527. Epub 2014 Dec 5.
8
New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.治疗急性髓系白血病的新策略，包括抗体及其他新型药物。
Hematology Am Soc Hematol Educ Program. 2005:143-50. doi: 10.1182/asheducation-2005.1.143.
9
Novel therapeutics in acute myeloid leukemia.急性髓系白血病的新型疗法
Curr Hematol Malig Rep. 2014 Jun;9(2):109-17. doi: 10.1007/s11899-014-0199-0.
10
Treatment of Relapsed/Refractory Acute Myeloid Leukemia.复发/难治性急性髓系白血病的治疗
Curr Treat Options Oncol. 2017 Mar;18(3):17. doi: 10.1007/s11864-017-0456-2.
引用本文的文献
1
Norchelerythrine from (Thunb.) Pers. promotes differentiation and apoptosis by activating DNA damage response in acute myeloid leukemia.紫堇科紫堇属植物珠芽地锦苗中的去甲白屈菜红碱通过激活急性髓系白血病中的DNA损伤反应促进细胞分化和凋亡。
Int J Oncol. 2025 Mar;66(3). doi: 10.3892/ijo.2025.5723. Epub 2025 Feb 7.
2
Identification of immunity- and ferroptosis-related signature genes as potential design targets for mRNA vaccines in AML patients.鉴定免疫和铁死亡相关特征基因作为 AML 患者 mRNA 疫苗的潜在设计靶点。
Aging (Albany NY). 2024 Aug 29;16(16):11939-11954. doi: 10.18632/aging.206068.
3
p200CUX1-regulated BMP8B inhibits the progression of acute myeloid leukemia via the MAPK signaling pathway.p200CUX1 调控的 BMP8B 通过 MAPK 信号通路抑制急性髓系白血病的进展。
Med Oncol. 2024 May 31;41(7):166. doi: 10.1007/s12032-024-02398-2.
4
The two sides of chromosomal instability: drivers and brakes in cancer.染色体不稳定性的两面：癌症中的驱动因素和刹车。
Signal Transduct Target Ther. 2024 Mar 29;9(1):75. doi: 10.1038/s41392-024-01767-7.
5
m5C methylation modification guides the prognostic value and immune landscapes in acute myeloid leukemia.m5C 甲基化修饰指导急性髓系白血病的预后价值和免疫图谱。
Aging (Albany NY). 2023 Sep 25;15(18):9858-9876. doi: 10.18632/aging.205059.
6
ZNF460-regulated COMMD7 Promotes Acute Myeloid Leukemia Proliferation Via the NF-κB Signaling Pathway.锌指蛋白 460 调控 COMMD7 通过 NF-κB 信号通路促进急性髓系白血病增殖。
Int J Med Sci. 2023 Feb 21;20(4):520-529. doi: 10.7150/ijms.80047. eCollection 2023.
7
Therapeutic Benefits of Selenium in Hematological Malignancies.硒在血液系统恶性肿瘤中的治疗益处。
Int J Mol Sci. 2022 Jul 19;23(14):7972. doi: 10.3390/ijms23147972.
8
Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment.高效细胞扩增和高通量药物敏感性筛选在白血病治疗中的应用。
Dis Markers. 2022 Jul 5;2022:4052591. doi: 10.1155/2022/4052591. eCollection 2022.
9
HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia.HCK 是急性髓系白血病中与免疫细胞浸润相关的潜在预后生物标志物。
Dis Markers. 2022 Mar 4;2022:3199589. doi: 10.1155/2022/3199589. eCollection 2022.
10
Evaluating Sarcopenia by Using the Bioelectrical Impedance Analysis in Patients with Acute Myeloid Leukemia After Chemotherapy.化疗后急性髓系白血病患者中使用生物电阻抗分析评估肌肉减少症
Int J Gen Med. 2022 Feb 9;15:1261-1269. doi: 10.2147/IJGM.S351241. eCollection 2022.
本文引用的文献
1
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.一项在新诊断为急性髓系白血病患者中进行的quizartinib 联合诱导和巩固化疗的 1 期研究。
Am J Hematol. 2018 Feb;93(2):213-221. doi: 10.1002/ajh.24974. Epub 2017 Dec 4.
2
Acute Myeloid Leukemia.急性髓系白血病
N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/NEJMra1406184.
3
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.瓜德西他滨（SGI-110）在骨髓增生异常综合征和急性髓系白血病患者中的安全性和耐受性：一项多中心、随机、剂量递增的1期研究。
Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19.
4
Acute Myeloid Leukemia Response Measures Other Than Complete Remission.除完全缓解外的急性髓系白血病反应评估指标
J Clin Oncol. 2015 Nov 1;33(31):3675-6. doi: 10.1200/JCO.2015.62.0864. Epub 2015 Aug 17.
5
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.伏沙罗辛联合阿糖胞苷对比安慰剂联合阿糖胞苷治疗初治复发或难治性急性髓系白血病患者（VALOR）：一项随机、对照、双盲、多中心3期研究
Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.
6
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.阿扎胞苷对比传统治疗方案用于新诊断的原始细胞比例>30%的老年急性髓系白血病患者的国际3期研究。
Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18.
7
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.地西他滨可改善急性髓性白血病且原始细胞计数较高的老年患者的预后。
Am J Hematol. 2015 Jul;90(7):E139-41. doi: 10.1002/ajh.24036. Epub 2015 May 28.
8
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.伏沙罗辛及伏沙罗辛联合小剂量阿糖胞苷（LDAC）与单纯小剂量阿糖胞苷治疗老年急性髓系白血病的疗效比较
Blood. 2015 May 7;125(19):2923-32. doi: 10.1182/blood-2014-10-608117. Epub 2015 Mar 24.
9
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.米哚妥林与阿扎胞苷用于复发及老年急性髓系白血病患者的I期研究。
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):428-432.e2. doi: 10.1016/j.clml.2015.02.017. Epub 2015 Feb 16.
10
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.与欧洲白血病网风险分类系统相比，医学研究理事会细胞遗传学分类在急性髓系白血病中的预后意义。
Br J Haematol. 2015 Aug;170(4):590-3. doi: 10.1111/bjh.13319. Epub 2015 Feb 25.
Zotero 插件